|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fingerhut A, Vassiliu P, Dervenis C,
Alexakis N and Leandros E: What is in a word: Pancreatoduodenectomy
or pancreaticoduodenectomy? Surgery. 142:428–429. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yu Y, Ramena G and Elble RC: The role of
cancer stem cells in relapse of solid tumors. Front Biosci (Elite
Ed). 4:1528–1541. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oettle H and Neuhaus P: Adjuvant therapy
in pancreatic cancer: A critical appraisal. Drugs. 67:2293–2310.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Renouf D and Moore M: Evolution of
systemic therapy for advanced pancreatic cancer. Expert Rev
Anticancer Ther. 10:529–540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Conroy T, Gavoille C, Samalin E, Ychou M
and Ducreux M: The role of the FOLFIRINOX regimen for advanced
pancreatic cancer. Curr Oncol Rep. 15:182–189. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Faris JE, Blaszkowsky LS, McDermott S,
Guimaraes AR, Szymonifka J, Huynh MA, Ferrone CR, Wargo JA, Allen
JN, Dias LE, et al: FOLFIRINOX in locally advanced pancreatic
cancer: The Massachusetts General Hospital Cancer Center
experience. Oncologist. 18:543–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Vishnu P and Roy V: Safety and efficacy of
nab-paclitaxel in the treatment of patients with breast cancer.
Breast Cancer (Auckl). 5:53–65. 2011.PubMed/NCBI
|
|
11
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: Groupe Tumeurs Digestives of Unicancer;
PRODIGE Intergroup: FOLFIRINOX versus gemcitabine for metastatic
pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vinogradov S and Wei X: Cancer stem cells
and drug resistance: The potential of nanomedicine. Nanomedicine
(Lond). 7:597–615. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shiozawa Y, Nie B, Pienta KJ, Morgan TM
and Taichman RS: Cancer stem cells and their role in metastasis.
Pharmacol Ther. 138:285–293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmied BM, Ulrich A, Matsuzaki H, Li CH
and Pour PM: In vitro pancreatic carcinogenesis. Ann Oncol. 10
Suppl 4:41–45. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Du Z, Qin R, Wei C, Wang M, Shi C, Tian R
and Peng C: Pancreatic cancer cells resistant to chemoradiotherapy
rich in ‘stem-cell-like’ tumor cells. Dig Dis Sci. 56:741–750.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lonardo E, Cioffi M, Sancho P, Crusz S and
Heeschen C: Studying pancreatic cancer stem cell characteristics
for developing new treatment strategies. J Vis Exp.
100:e528012015.
|
|
17
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ajani JA, Song S, Hochster HS and
Steinberg IB: Cancer stem cells: The promise and the potential.
Semin Oncol. 42 Suppl 1:S3–S17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
La Barre J: Hypotensive effects of the
completely dereserpinised extract of Rauwolfia vomitoria.
Arzneimittelforschung. 23:600–605. 1973.PubMed/NCBI
|
|
20
|
Gbolade A: Ethnobotanical study of plants
used in treating hypertension in Edo State of Nigeria. J
Ethnopharmacol. 144:1–10. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pesewu GA, Cutler RR and Humber DP:
Antibacterial activity of plants used in traditional medicines of
Ghana with particular reference to MRSA. J Ethnopharmacol.
116:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kweifio-Okai G: Antiinflammatory activity
of a Ghanaian antiarthritic herbal preparation: I. J
Ethnopharmacol. 33:263–267. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
La Barre J and Castiau J: Effect of
reserpine-free Rauwolfia vomitoria extract on gastric motility in
dogs. C R Seances Soc Biol Fil. 151:2222–2224. 1957.(In French).
PubMed/NCBI
|
|
24
|
Isaiah AM, Olawale O, Effiong EE,
Idongesit NJ, Fidelis UA and Friday UU: Vitamin e supplementation
with Rauwolfia vomitoria root bark extract improves hematological
indices. N Am J Med Sci. 4:86–89. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bemis DL, Capodice JL, Gorroochurn P, Katz
AE and Buttyan R: Anti-prostate cancer activity of a beta-carboline
alkaloid enriched extract from Rauwolfia vomitoria. Int J Oncol.
29:1065–1073. 2006.PubMed/NCBI
|
|
26
|
Iwu MM and Court WE: Root alkaloids of
Rauwolfia vomitoria afz. Planta Med. 32:88–99. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Beljanski M and Beljanski MS: Three
alkaloids as selective destroyers of cancer cells in mice. Synergy
with classic anticancer drugs. Oncology. 43:198–203. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen Q, Chao R, Chen H, Hou X, Yan H, Zhou
S, Peng W and Xu A: Antitumor and neurotoxic effects of novel
harmine derivatives and structure-activity relationship analysis.
Int J Cancer. 114:675–682. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yu J and Chen Q: Antitumor activities of
Rauwolfia vomitoria extract and potentiation of gemcitabine effects
against pancreatic cancer. Integr Cancer Ther. 13:217–225. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)). Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Amini S, Fathi F, Mobalegi J,
Sofimajidpour H and Ghadimi T: The expressions of stem cell
markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3,
Dppa4, and Esrrb in bladder, colon, and prostate cancer, and
certain cancer cell lines. Anat Cell Biol. 47:1–11. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vermeulen L, Todaro M, de Sousa Mello F,
Sprick MR, Kemper K, Alea Perez M, Richel DJ, Stassi G and Medema
JP: Single-cell cloning of colon cancer stem cells reveals a
multi-lineage differentiation capacity. Proc Natl Acad Sci USA.
105:13427–13432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim SY, Hong SH, Basse PH, Wu C, Bartlett
DL, Kwon YT and Lee YJ: Cancer stem cells protect non-stem cells
from anoikis: Bystander effects. J Cell Biochem. 117:2289–2301.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Goodell MA, McKinney-Freeman S and Camargo
FD: Isolation and characterization of side population cells.
Methods Mol Biol. 290:343–352. 2005.PubMed/NCBI
|
|
35
|
Richard V, Nair MG, Kumar Santhosh TR and
Pillai MR: Side population cells as prototype of chemoresistant,
tumor-initiating cells. BioMed Res Int. 2013:5172372013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takebe N, Harris PJ, Warren RQ and Ivy SP:
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog
pathways. Nat Rev Clin Oncol. 8:97–106. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
MacDonald BT, Tamai K and He X:
Wnt/β-catenin signaling: Components, mechanisms, and diseases. Dev
Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheng P, Sun X, Yin D, Xu F, Yang K, Qin
L, Dong Y, Guo F, Chen A, Zhang W, et al: Nanog down-regulates the
Wnt signaling pathway via β-catenin phosphorylation during
epidermal stem cell proliferation and differentiation. Cell Biosci.
5:52015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yong X, Tang B, Xiao YF, Xie R, Qin Y, Luo
G, Hu CJ, Dong H and Yang SM: Helicobacter pylori upregulates Nanog
and Oct4 via Wnt/β-catenin signaling pathway to promote cancer stem
cell-like properties in human gastric cancer. Cancer Lett.
374:292–303. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Takao Y, Yokota T and Koide H:
Beta-catenin up-regulates Nanog expression through interaction with
Oct-3/4 in embryonic stem cells. Biochem Biophys Res Commun.
353:699–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
An Y and Ongkeko WM: ABCG2: The key to
chemoresistance in cancer stem cells? Expert Opin Drug Metab
Toxicol. 5:1529–1542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li C, Lee CJ and Simeone DM:
Identification of human pancreatic cancer stem cells. Methods Mol
Biol. 568:161–173. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Salmaggi A, Boiardi A, Gelati M, Russo A,
Calatozzolo C, Ciusani E, Sciacca FL, Ottolina A, Parati EA, La
Porta C, et al: Glioblastoma-derived tumorospheres identify a
population of tumor stem-like cells with angiogenic potential and
enhanced multidrug resistance phenotype. Glia. 54:850–860. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nagare RP, Sneha S, Priya SK and Ganesan
TS: Cancer stem cells - Are surface markers alone sufficient? Curr
Stem Cell Res Ther. 12:37–44. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yu J, Ma Y, Drisko J and Chen Q: Antitumor
activities of Rauwolfia vomitoria extract and potentiation of
carboplatin effects against ovarian cancer. Curr Ther Res Clin Exp.
75:8–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
